Genelux (GNLX) EBIT Margin (2022 - 2024)

Genelux (GNLX) recorded quarterly EBIT Margin of 101437.5% in Q1 2024, down 2568.58% quarter-over-quarter from 3801.18% in Q1 2023, and down 9763632.0% on a YoY basis from N/an in Q2 2023.

Genelux (GNLX) EBIT Margin (2022 - 2024) Analysis & Trends

Genelux's EBIT Margin history runs 3 years deep, the most recent figure standing at 101437.5% for Q1 2024.

  • In Q1 2024, EBIT Margin fell 9763632.0% year-over-year to 101437.5%; the TTM figure through Dec 2024 stood at 396200.0% (down 38198529.0% YoY), while the FY2025 annual figure was 415175.0%, down 1897500.0% from the prior year.
  • EBIT Margin was 101437.5% for Q1 2024 at Genelux, down from 3801.18% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 57.67% in Q3 2022 to a low of 101437.5% in Q1 2024.
  • Historically, EBIT Margin has averaged 26288.11% across 3 years, with a median of 1886.3% in 2022.
  • Biggest YoY gain for EBIT Margin was 9763632 bps in 2024; the steepest drop was 9763632 bps in 2024.
  • A 3-year view of EBIT Margin shows it stood at 28.57% in 2022, then slumped by 13405 bps to 3801.18% in 2023, then tumbled by 2569 bps to 101437.5% in 2024.
  • The last three EBIT Margin figures came in at 101437.5% (Q1 2024), 3801.18% (Q1 2023), and 28.57% (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -6.43%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 38.10%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Genelux 129.36 Mn 129.36 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 -101,437.50%
Mar 31, 2023 -3,801.18%
Dec 31, 2022 28.57%
Sep 30, 2022 57.67%